HANSOH PHARMA (03692.HK): HS-20093 Gets Osteosarcoma Priority Review

NewTimeSpace News: On 22 September 2026, Hansoh Pharmaceutical Group Company Limited (stock code: 03692.HK) announced on a voluntary basis that the indication of its injectable HS-20093 (Risvutatug Rezetecan) for the treatment of osteosarcoma patients aged 12 years and above who have failed at least two prior lines of therapy was, on 14 September 2026, included in the priority review and approval procedure of China's National Medical Products Administration (NMPA). The announcement stated that the inclusion was based on positive results from the product's pivotal Phase III trial ARTEMIS-011. The announcement was made voluntarily by the Company.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.